Soleno Therapeutics, Inc.

Technical Analysis

SLNO exhibits concerning technical weakness, having declined significantly across multiple timeframes amid high volatility. Trading near its 52-week low with a negative beta, the stock shows persistent downward momentum and moves inversely to the broader market. While deeply oversold, there are currently no technical indicators signaling a reversal or recovery.

Fundamentals

The company demonstrates exceptional fundamentals with robust revenue growth and extraordinary profitability, highlighted by a 99.1% gross margin and 47.3% net profit margin. Financially, SLNO is exceptionally strong with minimal debt, high liquidity, and comfortable debt coverage ratios. However, operational efficiency shows mixed signals with a low asset turnover ratio and an extended cash conversion cycle, suggesting room for improvement in working capital management.

Valuation

SLNO's valuation presents a dichotomy: the high trailing P/E ratio suggests premium pricing, while the low forward P/E of 14.20 and compelling PEG ratio of 0.15 indicate significant earnings growth expectations. The elevated EV/EBITDA warrants caution, though without peer comparisons, the stock appears reasonably priced based on its anticipated growth trajectory.

Risk Assessment

The stock carries substantial volatility risk, evidenced by its extreme negative beta and severe maximum drawdown history. While the absence of significant short interest reduces squeeze risk, liquidity concerns remain for this volatile name. Investors must have high risk tolerance and be prepared for potentially sharp price swings.

Investment Recommendation

Consider for Aggressive Growth Portfolios SLNO presents a compelling opportunity for risk-tolerant investors seeking growth exposure. The company's exceptional fundamentals and attractive forward valuation metrics contrast sharply with its weak technical performance. While the volatility is substantial, the combination of strong profitability, clean balance sheet, and anticipated earnings growth suggests potential for significant upside once sentiment improves. This stock suits investors who can withstand near-term turbulence for potential long-term rewards.

RockFlow Model Forecast: Three Scenarios for 2026

Based on the analysis, here is a 12-month outlook for SLNO:

Catalysts: The primary catalyst for a rebound is a potential shift in market sentiment, driven by the company's exceptional profitability and compelling forward valuation metrics (low forward P/E and PEG ratio). The deeply oversold condition could also attract buyers seeking a technical bounce.

Risks: The significant risk is the persistence of negative momentum and high volatility, as the stock trades inverse to the broader market. A failure to improve operational efficiency or any disappointment in expected earnings growth could lead to further declines.

Outlook: While an analyst target is unavailable, the stock appears positioned for a potential recovery if it can overcome technical weakness. A realistic 12-month price range could be $45-$60, contingent on the company delivering on its growth trajectory and market sentiment turning positive; however, investors should be prepared for continued volatility.

Wall Street Consensus

Most Wall Street analysts are optimistic about Soleno Therapeutics, Inc.'s 12-month outlook, with consensus target around $39.07, indicating expected upside potential.

Overall, SLNO has investment potential but also faces challenges. Here are key factors to weigh before investing.

SLNO has demonstrated notably weak performance with substantial declines across multiple timeframes amid high volatility.

The stock has declined 7.61% over one month and 14.8% over three months, significantly underperforming the market by 18.77% during the latter period, reflecting persistent downward momentum. Its negative beta of -3.16 indicates unusually high volatility that moves inversely to the broader market.

Currently trading at $38.44, SLNO sits just 17.8% above its 52-week low and 57.4% below its 52-week high, suggesting the stock remains in deeply oversold territory. With a maximum drawdown of -57.92% over the past year, the security shows extremely weak momentum despite its depressed valuation levels.

Revenue & Profitability SLNO demonstrates robust revenue growth with quarterly revenue increasing from $66 million to $91.7 million, representing a 39% sequential growth. The company maintains exceptional profitability with a net profit margin of 47.3% in Q4 2025, supported by an extraordinarily high gross profit margin of 99.1%. This margin profile indicates strong pricing power and efficient cost management relative to revenue generation.

Financial Health The company exhibits exceptional financial strength with minimal debt exposure, reflected in a debt ratio of just 0.5% and a debt-to-equity ratio of 0.6%. SLNO maintains strong liquidity with a current ratio of 5.8 and cash ratio of 1.1, while generating healthy operating cash flow that covers debt obligations 18 times over. The interest coverage ratio of 30x further confirms the company's comfortable debt service capacity.

Operational Efficiency SLNO demonstrates solid operational performance with a return on equity of 9.6% and return on assets of 7.7%, indicating effective capital allocation. However, the asset turnover ratio of 0.16 suggests relatively low revenue generation per dollar of assets, though this is offset by the high fixed asset turnover of 38.6. The cash conversion cycle of 298 days highlights extended working capital requirements, primarily driven by high inventory days outstanding.

Valuation Level The stock's elevated TTM PE ratio of 97.93 suggests a historically high valuation, likely reflecting significant past growth expectations or earnings compression. However, the drastically lower forward PE of 14.20 and a very compelling PEG ratio of 0.15 indicate the market now anticipates strong near-term earnings growth that would rapidly normalize its valuation, pointing toward undervaluation based on future prospects.

Peer Comparison A direct peer comparison is not feasible as industry average data is unavailable. The analysis must therefore rely on absolute valuation metrics like the forward PE and PEG, which in isolation suggest the stock is reasonably priced relative to its anticipated growth trajectory. The high EV/EBITDA of 52.96 would typically warrant concern, but without a sector benchmark, its significance is difficult to contextualize against peers.

Volatility risk is extremely elevated, as indicated by the profoundly negative beta of -3.16. This suggests the stock tends to move sharply in the opposite direction of the broader market, and the substantial 57.92% maximum drawdown over the past year confirms its propensity for severe price declines. Investors should be prepared for highly erratic and potentially adverse price movements.

The absence of reported short interest reduces the immediate risk of a short squeeze but may also signal limited market attention or controversy. However, liquidity can be a concern for stocks with such characteristics, potentially leading to wide bid-ask spreads and difficulty executing trades, especially during periods of high volatility.